

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION ON THE GROUP'S PRODUCT PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM FOR INJECTION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Piperacillin Sodium and Tazobactam Sodium for Injection (Specification: 2.25g) submitted by Zhuhai United Laboratories Co., Ltd., Zhongshan Branch, a wholly-owned subsidiary of the Company, with the approval of China National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs (the "Consistency Evaluation").

Piperacillin sodium and tazobactam sodium for injection is a compound anti-infection drug composed by piperacillin (penicillin antibiotic) and tazobactam ( $\beta$ -lactamase inhibitor), applicable to treatment of moderate and severe infections caused by pneumonia, urinary tract infection, skin and soft tissue infection, septicemia, etc. Currently, this product is listed in Category B in the National Medical Insurance Drug List (2022 version). In addition, the Company's Piperacillin Sodium and Tazobactam Sodium for Injection (Specification: 4.5g) has passed the Consistency Evaluation in June 2022, and has won the bidding in the eighth batch of national centralised procurement of pharmaceuticals.

The approval will further help the Company to consolidate the advantageous position in the anti-infection field. The Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 26 July 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.